Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 41MicroRNA in disease regulationCancer, Lipids, and MetabolismCancer-related molecular mechanisms research

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Lauric Acid Modulates Cancer-Associated microRNA Expression and Inhibits the Growth of the Cancer Cell

Verma, Poonam, Ghosh, Amit, Ray, Manisha, Sarkar, Saurav·2020·Anti-Cancer Agents in Medicinal Chemistry
DOI 10.2174/1871520620666200310091719
Open this paper in CoChat — free account

Abstract

Background: microRNAs are known to regulate various protein-coding gene expression posttranscriptionally. Fatty acids are cell membrane constituents and are also known to influence the biological activities of the cells like signal transduction, growth and differentiation of the cells, apoptosis induction, and other physiological functions. In our experiments, we used lauric acid to analyse its effects on human cancerous cell lines. Objective: Our objective was to speculate the miRNA expression profile in lauric acid treated and untreated cancerous cell lines and further study the metabolic pathways of the targeted tumour suppressor and oncogenes. Methods: The KB cells and HepG2 cells were treated with lauric acid and miRNA was isolated and the expression of tumour suppressor and oncogenic miRNA was measured by quantitative PCR. The untreated cells were used as control. The metabolic pathways of the target tumour suppressor and oncogenes were examined by GeneMANIA software. Results: Interestingly, the lauric acid treatment suppresses the expression of oncogenic miRNA and significantly upregulated the expression of some tumour suppressor miRNAs. GeneMANIA metabolic pathway revealed that the upregulated tumour suppressor miRNAs regulate several cancer-associated pathways such as DNA damage, signal transduction p53 class mediator, stem cell differentiation, cell growth, cell cycle phase transition, apoptotic signalling pathway, cellular response to stress and radiation, etc. whereas oncogenic miRNAs regulate the cancer-associated pathway like cell cycle phase transition, apoptotic signalling pathway, cell growth, response to oxidative stress, immune response activating cell surface protein signalling pathway, cyclin-dependent protein kinase activity, epidermal growth factor receptor signalling pathways, etc. Conclusion: In our study, we found that lauric acid works as an anticancer agent by altering the expression of miRNAs.

Overview

Integrity signals

Registry

Crossref · 10.2174/1871520620666200310091719

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 1 references

Research works printed but not linked: 53

  1. Engelbrecht A.M.; Toit-Kohn J.L.; Ellis B.; Thomas M.; Nell T.; Smith R.; Differential induction of apoptosis and inhibition of the PI3-kinase pathway by saturated, monounsaturated and polyunsaturated fatty acids in a colon cancer cell model. Apoptosis 2008,13(11),1368-1377 · DOI
  2. Bocca C.; Bozzo F.; Gabriel L.; Miglietta A.; Conjugated linoleic acid inhibits Caco-2 cell growth via ERK-MAPK signaling pathway. J Nutr Biochem 2007,18(5),332-340 · DOI
  3. Jump D.B.; Clarke S.D.; Regulation of gene expression by dietary fat. Annu Rev Nutr 1999,19,63-90 · DOI
  4. Risérus U.; Fatty acids and insulin sensitivity. Curr Opin Clin Nutr Metab Care 2008,11(2),100-105 · DOI
  5. Calder P.C.; Functional roles of fatty acids and their effects on human health. JPEN J Parenter Enteral Nutr 2015,39(1)(Suppl.),18S-32S · DOI
  6. Dayrit F.M.; The properties of lauric acid and their significance in coconut oil. J Am Oil Chem Soc 2015,92,1-15 · DOI · Paper page
  7. Kappally S.; Shirwaikar A.; Shirwaikar A.; Coconut oil – a review of potential applications. Hygeia J D Med 2015,7,34-41
  8. Eyres L.; Eyres M.F.; Chisholm A.; Brown R.C.; Coconut oil consumption and cardiovascular risk factors in humans. Nutr Rev 2016,74(4),267-280 · DOI · Paper page
  9. Kadochi Y.; Mori S.; Fujiwara-Tani R.; Luo Y.; Nishiguchi Y.; Kishi S.; Fujii K.; Ohmori H.; Kuniyasu H.; Remodeling of energy metabolism by a ketone body and medium-chain fatty acid suppressed the proliferation of CT26 mouse colon cancer cells. Oncol Lett 2017,14(1),673-680 · DOI
  10. Fauser J.K.; Matthews G.M.; Cummins A.G.; Howarth G.S.; Induction of apoptosis by the medium-chain length fatty acid lauric acid in colon cancer cells due to induction of oxidative stress. Chemotherapy 2013,59(3),214-224 · DOI
  11. Pritchard C.C.; Cheng H.H.; Tewari M.; MicroRNA profiling: approaches and considerations. Nat Rev Genet 2012,13(5),358-369 · DOI · Paper page
  12. Ramachandran R.; Fausett B.V.; Goldman D.; Ascl1a regulates Müller glia dedifferentiation and retinal regeneration through a Lin-28-dependent, let-7 microRNA signalling pathway. Nat Cell Biol 2010,12(11),1101-1107 · DOI
  13. Esquela-Kerscher A.; Slack F.J.; Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer 2006,6(4),259-269 · DOI · Paper page
  14. Weng W.H.; Leung W.H.; Pang Y.J.; Hsu H.H.; Lauric acid can improve the sensitization of Cetuximab in KRAS/BRAF mutated colorectal cancer cells by retrievable microRNA-378 expression. Oncol Rep 2016,35(1),107-116 · DOI
  15. Mosmann T.; Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983,65(1-2),55-63 · DOI · Paper page
  16. Livak K.J.; Schmittgen T.D.; Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001,25(4),402-408 · DOI · Paper page
  17. Ibarguren M.; López D.J.; Escribá P.V.; The effect of natural and synthetic fatty acids on membrane structure, microdomain organization, cellular functions and human health. Biochim Biophys Acta 2014,1838(6),1518-1528 · DOI
  18. Li G.; Wang K.; Wang J.; Qin S.; Sun X.; Ren H.; miR-497-5p inhibits tumor cell growth and invasion by targeting SOX5 in non-small-cell lung cancer. J Cell Biochem 2019,120(6),10587-10595 · DOI
  19. Yang Q.; Yu W.; Han X.; Overexpression of microRNA‑101 causes anti‑tumor effects by targeting CREB1 in colon cancer. Mol Med Rep 2019,19(4),3159-3167 · DOI
  20. Lappano R.; Sebastiani A.; Cirillo F.; Rigiracciolo D.C.; Galli G.R.; Curcio R.; Malaguarnera R.; Belfiore A.; Cappello A.R.; Maggiolini M.; The lauric acid-activated signaling prompts apoptosis in cancer cells. Cell Death Discov 2017,3,17063 · DOI · Paper page
  21. De Matteis V.; Cascione M.; De Giorgi M.L.; Leporatti S.; Rinaldi R.; Encapsulation of thermo-sensitive lauric acid in silica shell: A green derivate for chemo-thermal therapy in breast cancer cell. Molecules 2019,24(11) · DOI
  22. Famurewa A.C.; Ufebe O.G.; Egedigwe C.A.; Nwankwo O.E.; Obaje G.S.; Virgin coconut oil supplementation attenuates acute chemotherapy hepatotoxicity induced by anticancer drug methotrexate via inhibition of oxidative stress in rats. Biomed Pharmacother 2017,87,437-442 · DOI
  23. Famurewa A.C.; Folawiyo A.M.; Enohnyaket E.B.; Azubuike-Osu S.O.; Abi I.; Obaje S.G.; Famurewa O.A.; Beneficial role of virgin coconut oil supplementation against acute methotrexate chemotherapy-induced oxidative toxicity and inflammation in rats. Integr Med Res 2018,7(3),257-263 · DOI
  24. Alex A.; Nair N.K.; Tomy S.; Elango K.; Achuthan C.R.; A study on the effect of virgin coconut oil on benzo(A) pyrene induced gastric neoplasia in mice. Int J Pharm Sci Res 2016,7(5),1948-1955 · DOI
  25. Farooqi A.A.; Fuentes-Mattei E.; Fayyaz S.; Raj P.; Goblirsch M.; Poltronieri P.; Calin G.A.; Interplay between epigenetic abnormalities and deregulated expression of microRNAs in cancer. Semin Cancer Biol 2019,58,47-55 · DOI
  26. Verma P.; Naik S.; Nanda P.; Banerjee S.; Naik S.; Ghosh A.; In vitro anticancer activity of virgin coconut oil and its fractions in liver and oral cancer cells. Anticancer Agents Med Chem 2019,19(18),2223-2230 · DOI · Paper page
  27. Zhao J.; Fang Z.; Zha Z.; Sun Q.; Wang H.; Sun M.; Qiao B.; Quercetin inhibits cell viability, migration and invasion by regulating miR-16/HOXA10 axis in oral cancer. Eur J Pharmacol 2019,847,11-18 · DOI
  28. Kolokythas A.; Miloro M.; Zhou X.; Review of MicroRNA deregulation in oral cancer. Part I. J Oral Maxillofac Res 2011,2(2) · DOI
  29. Takeshita F.; Patrawala L.; Osaki M.; Takahashi R.U.; Yamamoto Y.; Kosaka N.; Kawamata M.; Kelnar K.; Bader A.G.; Brown D.; Ochiya T.; Systemic delivery of synthetic microRNA-16 inhibits the growth of metastatic prostate tumors via downregulation of multiple cell-cycle genes. Mol Ther 2010,18(1),181-187 · DOI
  30. Calin G.A.; Cimmino A.; Fabbri M.; Ferracin M.; Wojcik S.E.; Shimizu M.; Taccioli C.; Zanesi N.; Garzon R.; Aqeilan R.I.; Alder H.; Volinia S.; Rassenti L.; Liu X.; Liu C.G.; Kipps T.J.; Negrini M.; Croce C.M.; MiR-15a and miR-16-1 cluster functions in human leukemia. Proc Natl Acad Sci USA 2008,105(13),5166-5171 · DOI
  31. Kulkarni V.; Uttamani J.R.; Naqvi A.R.; Nares S.; microRNAs: Emerging players in oral cancers and inflammatory disorders. Tumour Biol 2017,39(5) · DOI
  32. Yang J.; Cao Y.; Sun J.; Zhang Y.; Curcumin reduces the expression of Bcl-2 by upregulating miR-15a and miR-16 in MCF-7 cells. Med Oncol 2010,27(4),1114-1118 · DOI
  33. Saini S.; Arora S.; Majid S.; Shahryari V.; Chen Y.; Deng G.; Yamamura S.; Ueno K.; Dahiya R.; Curcumin modulates microRNA-203-mediated regulation of the Src-Akt axis in bladder cancer. Cancer Prev Res (Phila) 2011,4(10),1698-1709 · DOI
  34. Cimmino A.; Calin G.A.; Fabbri M.; Iorio M.V.; Ferracin M.; Shimizu M.; Wojcik S.E.; Aqeilan R.I.; Zupo S.; Dono M.; Rassenti L.; Alder H.; Volinia S.; Liu C.G.; Kipps T.J.; Negrini M.; Croce C.M.; miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci USA 2005,102(39),13944-13949 · DOI
  35. Cheng B.; Ding F.; Huang C.Y.; Xiao H.; Fei F.Y.; Li J.; Role of miR-16-5p in the proliferation and metastasis of hepatocellular carcinoma. Eur Rev Med Pharmacol Sci 2019,23(1),137-145
  36. Lim H.S.; Kim C.S.; Kim J.S.; Yu S.K.; Go D.S.; Lee S.A.; Moon S.M.; Chun H.S.; Kim S.G.; Kim D.K.; Suppression of oral carcinoma oncogenic activity by microRNA-203 via Down-regulation of SEMA6A. Anticancer Res 2017,37(10),5425-5433
  37. Mahati S.; Xiao L.; Yang Y.; Mao R.; Bao Y.; miR-29a suppresses growth and migration of hepatocellular carcinoma by regulating CLDN1. Biochem Biophys Res Commun 2017,486(3),732-737 · DOI
  38. Zhou W.; Zou B.; Liu L.; Cui K.; Gao J.; Yuan S.; Cong N.; MicroRNA-98 acts as a tumor suppressor in hepatocellular carcinoma via targeting SALL4. Oncotarget 2016,7(45),74059-74073 · DOI
  39. Ting H.J.; Messing J.; Yasmin-Karim S.; Lee Y.F.; Identification of microRNA-98 as a therapeutic target inhibiting prostate cancer growth and a biomarker induced by vitamin D. J Biol Chem 2013,288(1),1-9 · DOI
  40. Koduru S.V.; Leberfinger A.N.; Kawasawa Y.I.; Mahajan M.; Gusani N.J.; Sanyal A.J.; Ravnic D.J.; Non-coding RNAs in Various Stages of Liver Disease Leading to Hepatocellular Carcinoma: Differential Expression of miRNAs, piRNAs, lncRNAs, circRNAs, and sno/mt-RNAs. Sci Rep 2018,8(1),7967 · DOI
  41. Li L.M.; Hu Z.B.; Zhou Z.X.; Chen X.; Liu F.Y.; Zhang J.F.; Shen H.B.; Zhang C.Y.; Zen K.; Serum microRNA profiles serve as novel biomarkers for HBV infection and diagnosis of HBV-positive hepatocarcinoma. Cancer Res 2010,70(23),9798-9807 · DOI
  42. Zhao X.; Yang Z.; Li G.; Li D.; Zhao Y.; Wu Y.; Robson S.C.; He L.; Xu Y.; Miao R.; Zhao H.; The role and clinical implications of microRNAs in hepatocellular carcinoma. Sci China Life Sci 2012,55(10),906-919 · DOI
  43. Li J.; Huang H.; Sun L.; Yang M.; Pan C.; Chen W.; Wu D.; Lin Z.; Zeng C.; Yao Y.; Zhang P.; Song E.; MiR-21 indicates poor prognosis in tongue squamous cell carcinomas as an apoptosis inhibitor. Clin Cancer Res 2009,15(12),3998-4008 · DOI
  44. Gombos K.; Horváth R.; Szele E.; Juhász K.; Gocze K.; Somlai K.; Pajkos G.; Ember I.; Olasz L.; miRNA expression profiles of oral squamous cell carcinomas. Anticancer Res 2013,33(4),1511-1517
  45. Roy S.; Khanna S.; Hussain S.R.; Biswas S.; Azad A.; Rink C.; Gnyawali S.; Shilo S.; Nuovo G.J.; Sen C.K.; MicroRNA expression in response to murine myocardial infarction: miR-21 regulates fibroblast metalloprotease-2 via phosphatase and tensin homologue. Cardiovasc Res 2009,82(1),21-29 · DOI
  46. Chang C.C.; Yang Y.J.; Li Y.J.; Chen S.T.; Lin B.R.; Wu T.S.; Lin S.K.; Kuo M.Y.; Tan C.T.; MicroRNA-17/20a functions to inhibit cell migration and can be used a prognostic marker in oral squamous cell carcinoma. Oral Oncol 2013,49(9),923-931 · DOI
  47. Wagenaar T.R.; Zabludoff S.; Ahn S.M.; Allerson C.; Arlt H.; Baffa R.; Cao H.; Davis S.; Garcia-Echeverria C.; Gaur R.; Huang S.M.; Jiang L.; Kim D.; Metz-Weidmann C.; Pavlicek A.; Pollard J.; Reeves J.; Rocnik J.L.; Scheidler S.; Shi C.; Sun F.; Tolstykh T.; Weber W.; Winter C.; Yu E.; Yu Q.; Zheng G.; Wiederschain D.; Anti-miR-21 suppresses hepatocellular carcinoma growth via broad transcriptional network deregulation. Mol Cancer Res 2015,13(6),1009-1021 · DOI
  48. Tao J.; Jiang L.; Chen X.; Roles of microRNA in liver cancer. Liver Res 2018,2(2),61-72 · DOI
  49. Tomimaru Y.; Eguchi H.; Nagano H.; Wada H.; Tomokuni A.; Kobayashi S.; Marubashi S.; Takeda Y.; Tanemura M.; Umeshita K.; Doki Y.; Mori M.; MicroRNA-21 induces resistance to the anti-tumour effect of interferon-α/5-fluorouracil in hepatocellular carcinoma cells. Br J Cancer 2010,103(10),1617-1626 · DOI
  50. Pan X.; Wang Z.X.; Wang R.; MicroRNA-21: a novel therapeutic target in human cancer. Cancer Biol Ther 2010,10(12),1224-1232 · DOI
  51. Gong J.; He X.X.; Tian A.; Emerging role of microRNA in hepatocellular carcinoma (Review). Oncol Lett 2015,9(3),1027-1033 · DOI
  52. Su X.; Wang H.; Ge W.; Yang M.; Hou J.; Chen T.; Li N.; Cao X.; An in vivo method to identify microRNA targets not predicted by computation algorithms: p21 targeting by miR-92a in cancer. Cancer Res 2015,75(14),2875-2885 · DOI
  53. Drury R.E.; O’Connor D.; Pollard A.J.; The clinical application of MicroRNAs in infectious disease. Front Immunol 2017,8,1182 · DOI

Cited by

Metadata

Authors
Verma, P., Ghosh, A., Ray, M., & Sarkar, S.
Affiliations
All India Institute of Medical Sciences Bhubaneswar (IN)
Corresponding author
Ghosh, Amit
ORCID
Venue
Anti-Cancer Agents in Medicinal Chemistry
Publisher
Bentham Science Publishers Ltd.
Published
2020-07-03
Volume
20
Issue
7
Pages
834-844
ISSN
  • 1568-0118 (ISSN-L)
  • 1871-5206
DOI
10.2174/1871520620666200310091719
OpenAlex
W3011128053
Cited by
41
References
1
Citations by year
2026: 3 · 2025: 12 · 2024: 19 · 2023: 5 · 2022: 2
FWCI
0.69
Type
journal article
Language
en
Open access
closed
Locations
  • Anti-Cancer Agents in Medicinal Chemistry (publishedVersion)
  • PubMed (publishedVersion)
Funders
All India Institute of Medical Sciences, Bhubaneswar, Odisha, India (IMF/07/2017)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › MicroRNA in disease regulation
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer-related molecular mechanisms research
Keywords
lauric acid, microRNA expression, tumor suppressor microRNA, oncogenic microRNA, fatty acids, anticancer agents, KB cells, HepG2 cells, tumor cell growth inhibition, cell cycle, DNA damage, metabolic pathways
MeSH terms
Antineoplastic Agents, Cell Survival, Dose-Response Relationship, Drug, Drug Screening Assays, Antitumor, Humans, KB Cells, Lauric Acids, Structure-Activity Relationship, MicroRNAs, Cell Proliferation, Hep G2 Cells

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review